Known targets — ChEMBL curated mechanism
CSF1RFGFR1FGFR3FLT1FLT4ITKKDRKITLCKPDGFRAPDGFRB
The experimentally established mechanism targets of Pazopanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 15/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 10/20 | 0.97 |
| ▸ | PDGFRA known ✓ | P16234 | 9/20 | 0.97 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.97 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.97 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 0.97 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.97 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.97 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.97 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.97 |
| ▸ | PLK4 | O00444 | 1/20 | 0.97 |
| ▸ | AURKA | O14965 | 1/20 | 0.97 |
| ▸ | GAK | O14976 | 1/20 | 0.97 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pazopanib SCHEMBL159487 | 0.99 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29386934 | 0.99 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL588608 | 0.98 | KDR (1.00) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29392503 | 0.98 | KDR (1.00) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29520402 | 0.97 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL3173301 | 0.96 | KDR (0.95) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025438 | 0.93 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025440 | 0.93 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025441 | 0.92 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 | |
| SCHEMBL22720091 | 0.92 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231265-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GUPTA MANISH K (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2566331-B1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MFG PTE LTD (SG) | 2014-09-03 | — | — | EP | disclosed |
| EP-2566331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2013-03-13 | — | — | EP | disclosed |
| US-20130023550-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE, LTD (SG) | 2013-01-24 | — | — | US | disclosed |
| US-20130012531-A1 | TREATMENT METHOD | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-01-10 | — | — | US | disclosed |
| EP-2521550-A1 | TREATMENT METHOD | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2012-11-14 | — | — | EP | disclosed |
| US-20120232102-A1 | Methods Of Administration And Treatment | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-09-13 | — | — | US | disclosed |
| EP-2490536-A1 | COMPOSITIONS AND PROCESSES | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2012-08-29 | — | — | EP | disclosed |
| EP-2329821-B1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GLAXOSMITHKLINE LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012103060-A1 | METHOD OF ADMINISTRATION AND TREATMENT | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-08-02 | — | — | WO | disclosed |
| US-20070208023-A1 | Cancer Treatment Method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007064753-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064752-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1755394-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060252943-A1 | Chemical process | SMITHKLINE BEECHAM CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1515955-A4 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006020564-A1 | PYRIMIDIN DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005105094-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1515955-A2 | CHEMICAL PROCESS | SmithKline Beecham Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106416-A2 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208023-A1 | Cancer Treatment Method | TP53, TYMP, TOP2A | KDR 1918/4885KIT 295/4885PDGFRA 1333/4885 |
| US-20120232102-A1 | Methods Of Administration And Treatment | AGER, VEGFA, FLT4 | KDR 5/4885KIT 696/4885PDGFRA 61/4885 |
| US-20130023550-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, PYGL, G6PC1 | KDR 25/4885KIT 419/4885PDGFRA 191/4885 |
| US-20150231265-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | KDR 65/4885KIT 385/4885PDGFRA 333/4885 |
| US-20130012531-A1 | TREATMENT METHOD | FLT4, VEGFA, FLT1 | KDR 4/4885KIT 94/4885PDGFRA 30/4885 |
| US-20060252943-A1 | Chemical process | KDR, FLT4, FLT1 | KDR 1/4885KIT 57/4885PDGFRA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.